507 related articles for article (PubMed ID: 32716410)
1. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of
Jiao M; Mingsong T; Hao J; Chunyin Z
Hell J Nucl Med; 2023; 26(2):123-131. PubMed ID: 37527048
[TBL] [Abstract][Full Text] [Related]
3. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
4. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
5. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of
Ma H; Kan Y; Yang JG
Acta Radiol; 2021 Sep; 62(9):1217-1228. PubMed ID: 32985224
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography for suspected primary and postoperative pyogenic spondylitis.
Zhang Q; Feng H; Li J; Feng R
J Orthop Surg Res; 2023 Jan; 18(1):23. PubMed ID: 36627651
[TBL] [Abstract][Full Text] [Related]
8. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
10.
Kan Y; Zhang S; Wang W; Liu J; Yang J; Wang Z
Acta Radiol; 2018 Dec; 59(12):1466-1474. PubMed ID: 29566550
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
Treglia G; Castaldi P; Rindi G; Giordano A; Rufini V
Endocrine; 2012 Aug; 42(1):80-7. PubMed ID: 22350660
[TBL] [Abstract][Full Text] [Related]
12. Detection of Bone Metastases by
Tian R; Xie Q; Yu F; Du C; Yao X; Zang S; Zhang C; Zhang P; Shao G; Yang Z; Wang F; Yu J
Contrast Media Mol Imaging; 2022; 2022():1750132. PubMed ID: 36447752
[TBL] [Abstract][Full Text] [Related]
13. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
14. The utility of
Zhang Q; Xi Y; Li D; Yuan Z; Dong J
J Orthop Surg Res; 2020 Jun; 15(1):229. PubMed ID: 32571371
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
Lee DY; Kim YI
Clin Nucl Med; 2019 Oct; 44(10):777-783. PubMed ID: 31283601
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis.
Ruan D; Zhao L; Cai J; Xu W; Sun L; Li J; Zhang J; Chen X; Chen H
Theranostics; 2023; 13(13):4694-4710. PubMed ID: 37649615
[No Abstract] [Full Text] [Related]
17. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors.
Partelli S; Rinzivillo M; Maurizi A; Panzuto F; Salgarello M; Polenta V; Delle Fave G; Falconi M
Neuroendocrinology; 2014; 100(4):293-9. PubMed ID: 25301162
[TBL] [Abstract][Full Text] [Related]
18. Value of [
Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM
EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
